Aegis Sciences Corporation announces it has been awarded $6.6 million NIH grant to rapidly expand COVID-19 Test Capacity
02 sept. 2020 11h05 HE
|
Aegis Sciences Corporation
NASHVILLE, Tenn., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative medication compliance testing and consulting...
Americans are not optimistic that a vaccine for the COVID-19 virus will be available to the public before the end of the year
02 sept. 2020 11h00 HE
|
The Logit Group
Once available, only two thirds anticipate that they will personally get the vaccination. PORT HURON, Michigan, Sept. 02, 2020 (GLOBE NEWSWIRE) -- With considerable efforts underway to develop...
TRACER to support Akston Biosciences’ Phase 1 clinical study of AKS-452, an innovative anti-COVID-19 vaccine
01 sept. 2020 12h41 HE
|
Akston Biosciences
BEVERLY, Mass., USA & GRONINGEN, the Netherlands, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Today, TRACER Europe B.V. (“TRACER”), a Clinical Research Organization (CRO) specializing in fast-track...
Aegis Sciences Corporation Announces National Launch of COVID-19 Antibody Testing Utilizing Convenient Dry Blood Spot Technology
31 août 2020 10h30 HE
|
Aegis Sciences Corporation
NASHVILLE, Tenn., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative medication compliance testing and consulting services...
Codex DNA Demonstrates Momentum Toward Mission of Building World’s First Vaccine Printer and Global Vaccine Network
25 août 2020 10h24 HE
|
Codex
San Diego, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Codex DNA, Inc., creators of the world’s first fully automated system for high-throughput writing of DNA, today announced critical advancements in its...
COVID-19 Drug Candidate Brilacidin Achieves a Selectivity Index Among the Highest Reported, Exhibiting Potent Anti-SARS-CoV-2 Activity at Low Concentrations; Clinical Trial Forthcoming
24 août 2020 08h00 HE
|
Innovation Pharmaceuticals Inc.
Preliminary data shows Brilacidin’s Selectivity Index (SI), a ratio that compares a drug’s cytotoxicity and antiviral activity, to be greater than 300 in a human lung epithelial cell lineBrilacidin’s...
Pfizer und BioNTech veröffentlichen erste positive Daten zu mRNA-basiertem Hauptimpfstoffkandidaten BNT162b2 gegen COVID-19
20 août 2020 20h16 HE
|
BioNTech SE
BNT162b2 induzierte in einer Phase-1-Studie in den USA 7 Tage nach der zweiten 30µg-Dosis mit BNT162b2 in jüngeren Erwachsenen (18-55 Jahre) SARS-CoV-2-neutralisierende geometrische Titer-Mittelwerte...
Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
20 août 2020 20h16 HE
|
BioNTech SE
In a Phase 1 study in the U.S., at 7 days after a second dose of 30ug, BNT162b2 elicited SARS-CoV-2–neutralizing geometric mean titers (GMTs) in younger adults (18-55 years of age) that were 3.8 times...
Professor Gordon Dougan Receives the 2020 Albert B. Sabin Gold Medal
13 août 2020 10h00 HE
|
The Sabin Vaccine Institute
Washington, D.C., Aug. 13, 2020 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute (Sabin) today announced that it has awarded its annual Albert B. Sabin Gold Medal to Gordon Dougan, FRS, professor in...
Pfizer und BioNTech geben Liefervereinbarung mit Kanada für mRNA-basierten Impfstoffkandidaten BNT162 bekannt
05 août 2020 08h00 HE
|
BioNTech SE
Lieferung im Verlauf von 2021, vorbehaltlich der Zulassung durch das kanadische GesundheitsministeriumDie Vereinbarung ist Teil der globalen Bemühungen von Pfizer und BioNTech, die Pandemie zu...